Drug intelligence / Profile preview

SLV-351

Development stage: Phase 1
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

SLV-351 is an investigational small molecule drug that was originally developed by Solvay and later by AbbVie for the treatment of central nervous system (CNS) disorders, specifically within the therapeutic area of nervous system diseases. The precise mechanism of action for SLV-351 remains undefined or unknown. The drug was administered orally and reached Phase 1 clinical trials in healthy volunteers, but development was discontinued after early-stage studies[1][2][3][4]. No approved indications or known adverse events have been reported.

Targets

HRH3 (Histamine Receptor H3)

Beyond the preview

Go deeper on SLV-351.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLV-351.

Explore the full profile